Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7785-7794
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7785
Table 1 Clinical features of patients with adult-onset hypophosphatemic osteomalacia

Sex/age
Location of pain
Previous misdiagnosis before OM diagnosis
Weakness (MRC grade)
Gait
Gower sign
Height loss (cm)
1F/52Low back, left scapula and chest wall, bilateral mid-thighN/AHip flexor - 4Bilateral compensated Trendelenburg gait(-)(-)
Hip abductor - 3
2M/62Thoracic back, bilateral chest wall and kneeN/ANegativeNormal(-)170 to 166
3F/55Thoracic and low back, bilateral flank, left shoulderOsteoporotic compression fractureNegativeNormal(-)159 to 153
4F/76Low back, right shoulder, left kneePathological scapular fractureNegativeNormal(-)145 to 143
5M/62Low back, bilateral chest wall buttock, and flank, left heelPolymyalgia rheumatica. OsteoporosisNTBilateral compensated Trendelenburg gait(+)164 to 161
6F/74Neck, low back, bilateral shoulder, ASIS, knee, and anklePolymyalgia rheumatica. Somatization syndromeU/E proximal - 4Bilateral compensated Trendelenburg gait(+)150 to 144
L/E proximal - 4
7M/54Low back, bilateral chest wall, right hip, thigh, and kneeStress fracture of tibia. Osteoporotic compression fractureL/E proximal - 4Bilateral compensated Trendelenburg gait(+)171 to 165
8M/61Low back, bilateral thigh and calfN/AU/E proximal - 3Bilateral compensated Trendelenburg gait(+)158 to 151
L/E proximal - (hip abductor - 0, hip flexor, knee extensor, knee flexor - 4)
L/E distal - 4
Table 2 Sites of increased radiotracer uptake on bone scintigraphy
Spine
Girdles
Long bone (focal)
Long bone (pseudo-reactivation of the growth plate)
Hand and Foot
Rib cage
Others
C
T
L
S
Scapula
Pelvis
Humerus
Femur
Tibia
Patella
Femur
Tibia
Carpals
Calcaneus
Mid tarsals
Meta tarsals
CV/CT JT
CC jnc
Rosary
Arc
Mandible
Sternum
1
2
3
4
5
6
7
8
Table 3 Etiology, treatment, and outcome of adult-onset hypophosphatemic osteomalacia

Etiology
Onset to diagnosis (mo)
ADV dose (mg/d)
ADV duration (yr)
Medication change
Time to symptom improvement (mo)
Time to normalization of phosphate (mo)
1Tumor-induced osteomalacia25N/AN/AN/A7 d2 d
2ADV-induced nephropathy25106Keep ADV3Never
3ADV-induced nephropathy241011Change to ETV0.53.5
4ADV-induced nephropathy61010Discontinuation of ADV33
5ADV-induced nephropathy9Unknown11Change to ETV28
6Light-chain nephropathy due to multiple myeloma14N/AN/AN/A1Never
7ADV-induced nephropathy27104Change to ETV29
8ADV-induced nephropathy61107Change to TAF11